9-methoxy-2-amino-1,2,3,4-tetrahydroanthracene | 179041-74-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 9-methoxy-2-amino-1,2,3,4-tetrahydroanthracene
• 英文别名: 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine；9-methoxy-1,2,3,4-tetrahydroanthracen-2-amine
• CAS: 179041-74-8
• 化学式: C₁₅H₁₇NO
• 分子量: 227.306
• InChiKey: XZOPIEFNQZTGHL-UHFFFAOYSA-N

物化性质

• 沸点：
  409.8±45.0 °C(predicted)
• 密度：
  1.125±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酰氯 、 9-methoxy-2-amino-1,2,3,4-tetrahydroanthracene 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以85%的产率得到N-(9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-yl)-acetamide
  参考文献：
  名称：

  Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors

  摘要：

  Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding alpha-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[I-125]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over tho se of tetrahydro anthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K-i = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K-i = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K-i = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K-i), melatonin gave melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.

  DOI：

  10.1021/jm960219h
• 作为产物：
  描述：

  1-羟基-2-萘甲酸 以95%的产率得到9-methoxy-2-amino-1,2,3,4-tetrahydroanthracene
  参考文献：
  名称：

  Tricyclic amides

  摘要：

  该发明涉及一种选择自以下公式(I)的化合物：##STR1## 其中R.sub.7，R.sub.8，Y，n和A如描述中定义，并含有相同化合物的药物产品，适用于治疗褪黑激素系统障碍。

  公开号：

  US05712312A1

文献信息

• Amides tricycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：ADIR ET COMPAGNIE

  公开号：EP0737670A1

  公开（公告）日：1996-10-16

  L'invention concerne les composés de formule (I) : dans laquelle R7, R8, Y, n et A sont tels que définis dans la description. Médicaments.

  本发明涉及式 (I) 化合物： 其中 R7、R8、Y、n 和 A 如说明书中所定义。 药物。
• US5712312A
  申请人：——

  公开号：US5712312A

  公开（公告）日：1998-01-27
• US5849781A
  申请人：——

  公开号：US5849781A

  公开（公告）日：1998-12-15
• Synthesis of 2-Amido-2,3-dihydro-1<i>H</i>-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors
  作者：Monique Mathé-Allainmat、Florence Gaudy、Sames Sicsic、Anne-Laure Dangy-Caye、Shuren Shen、Béatrice Brémont、Zohra Benatalah、Michel Langlois、Pierre Renard、Philippe Delagrange

  DOI：10.1021/jm960219h

  日期：1996.1.1

  Tetrahydroanthracene, tetrahydrophenanthrene, and tetrahydrophenalene moieties were used to design novel constrained melatoninergic agents. Compounds 1 and 2 were synthesized from the cyclization of the aryl succinic acids 6a,b followed by catalytic reduction, Curtius degradation to the amino derivatives, and acetylation. The phenalene derivatives 3 were prepared by cyclization of the aza lactones of the corresponding alpha-N-acetyl amino acids. The ketone derivatives were reduced directly by catalytic hydrogenation to produce the compounds 3. The different compounds were evaluated in vitro in binding assays using 2-[I-125]iodomelatonin and chicken brain membranes. Melatonin and 2-acetamido-8-methoxytetralin were used as the reference compounds. The results showed the superiority of the dihydrophenalene framework 3 over tho se of tetrahydro anthracene and tetrahydrophenanthrene. 3a had relatively good affinity for melatonin receptors (K-i = 28.7 nM). Introduction of an additional methoxy group gave a derivative (3c) with nanomolar affinity (K-i = 0.7 nM), confirming the existence of a secondary binding site in the receptor which has been described previously. An increase in the affinity was also observed with the propionamido derivative 3e (K-i = 6.0 nM). The potential agonist properties of the compound 3e were evaluated on the dermal melanocytes of Xenopus laevis tadpoles. At the concentration of 2.3 nM (5 x K-i), melatonin gave melanophore index value of 1. Similarly to melatonin, 3e was shown to be a potent agonist of the melanosome aggregation.
• Tricyclic amides
  申请人：Adir et Compagnie

  公开号：US05712312A1

  公开（公告）日：1998-01-27

  The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

  该发明涉及一种选择自以下公式(I)的化合物：##STR1## 其中R.sub.7，R.sub.8，Y，n和A如描述中定义，并含有相同化合物的药物产品，适用于治疗褪黑激素系统障碍。